BR0210207A - Derivados de pirrolidina como inibidores do fator xa - Google Patents

Derivados de pirrolidina como inibidores do fator xa

Info

Publication number
BR0210207A
BR0210207A BR0210207-2A BR0210207A BR0210207A BR 0210207 A BR0210207 A BR 0210207A BR 0210207 A BR0210207 A BR 0210207A BR 0210207 A BR0210207 A BR 0210207A
Authority
BR
Brazil
Prior art keywords
factor inhibitors
pyrrolidine derivatives
factor
inhibitors
derivatives
Prior art date
Application number
BR0210207-2A
Other languages
English (en)
Inventor
Chuen Chan
Julie Nicole Hamblin
Henry Anderson Kelly
Nigel Paul King
Andrew Mcmurtrie Mason
Vipulkumar Kantibhai Patel
Stefan Senger
Gita Punjabhai Shah
Nigel Stephen Watson
Helen Elisabeth Weston
Caroline Whitworth
Robert John Young
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of BR0210207A publication Critical patent/BR0210207A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/12—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

"DERIVADOS DE PIRROLIDINA COMO INIBIDORES DO FATOR XA". A invenção relaciona-se aos compostos de fórmula (I), aos processos para a sua preparação, às composições farmacêuticas contendo os mesmos e ao seu uso em medicina, particularmente ao uso na melhora de uma condição clínica para a qual um inibidor do Fator Xa é indicado.
BR0210207-2A 2001-06-08 2002-06-06 Derivados de pirrolidina como inibidores do fator xa BR0210207A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0114005.2A GB0114005D0 (en) 2001-06-08 2001-06-08 Chemical compounds
PCT/GB2002/002721 WO2002100830A1 (en) 2001-06-08 2002-06-06 Pyrrolidine derivatives as factor xa inhibitors

Publications (1)

Publication Number Publication Date
BR0210207A true BR0210207A (pt) 2004-08-03

Family

ID=9916209

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0210207-2A BR0210207A (pt) 2001-06-08 2002-06-06 Derivados de pirrolidina como inibidores do fator xa

Country Status (28)

Country Link
US (4) US7186717B2 (pt)
EP (1) EP1395553B1 (pt)
JP (1) JP4242274B2 (pt)
KR (1) KR100877245B1 (pt)
CN (1) CN1256324C (pt)
AR (1) AR036086A1 (pt)
AT (1) ATE289294T1 (pt)
AU (1) AU2002311451B2 (pt)
BR (1) BR0210207A (pt)
CA (1) CA2449629A1 (pt)
CO (1) CO5540285A2 (pt)
CZ (1) CZ20033325A3 (pt)
DE (1) DE60203006T2 (pt)
DK (1) DK1395553T3 (pt)
ES (1) ES2235050T3 (pt)
GB (1) GB0114005D0 (pt)
HU (1) HUP0400156A3 (pt)
IL (1) IL159195A0 (pt)
MX (1) MXPA03011384A (pt)
MY (1) MY136859A (pt)
NO (1) NO326689B1 (pt)
NZ (1) NZ530004A (pt)
PL (1) PL368082A1 (pt)
PT (1) PT1395553E (pt)
SI (1) SI1395553T1 (pt)
TW (1) TWI298719B (pt)
WO (1) WO2002100830A1 (pt)
ZA (1) ZA200309367B (pt)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0114005D0 (en) * 2001-06-08 2001-08-01 Glaxo Group Ltd Chemical compounds
GB0130705D0 (en) * 2001-12-21 2002-02-06 Glaxo Group Ltd Chemical compounds
GB0228533D0 (en) * 2002-12-06 2003-01-15 Glaxo Group Ltd Crystalline form
GB0228552D0 (en) * 2002-12-06 2003-01-15 Glaxo Group Ltd Chemical compounds
US20050119266A1 (en) * 2003-10-01 2005-06-02 Yan Shi Pyrrolidine and piperidine derivatives as factor Xa inhibitors
PL1637141T3 (pl) 2004-09-21 2012-04-30 Trobio Ab Stabilizowana kompozycja proteazy zawierająca proteazę serynową, pochodne morfoliny i odwracalne inhibitory tej proteazy serynowej
JP4912314B2 (ja) * 2004-10-26 2012-04-11 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 因子Ｘａ化合物
WO2006110726A2 (en) * 2005-04-11 2006-10-19 Glaxo Group Limited Dosage formulations and methods of treatment and prevention
CN102380100A (zh) * 2005-09-22 2012-03-21 特罗比奥股份公司 稳定的蛋白酶组合物
CA2621059C (en) * 2005-09-22 2013-08-13 Trobio Ab Stabilized protease composition
DE102007028319A1 (de) 2007-06-20 2008-12-24 Bayer Healthcare Ag Substituierte Oxazolidinone und ihre Verwendung
DE102007028407A1 (de) 2007-06-20 2008-12-24 Bayer Healthcare Ag Substituierte Oxazolidinone und ihre Verwendung
DE102007028406A1 (de) 2007-06-20 2008-12-24 Bayer Healthcare Ag Substituierte Oxazolidinone und ihre Verwendung
HRP20190245T1 (hr) * 2013-04-26 2019-04-05 Sanofi Tartratna sol [(s)-2-[metil-3-(2-okso-pirolidin-1-il)-benzensulfonilamino]-3-(4-metil piperazin-1 -il)-3-okso-propril]amida 5-kloro-tiofen-2-karboksilne kiseline
DE102014108210A1 (de) 2014-06-11 2015-12-17 Dietrich Gulba Rodentizid
EP3078378B1 (en) 2015-04-08 2020-06-24 Vaiomer Use of factor xa inhibitors for regulating glycemia
EP4070658A1 (de) 2021-04-06 2022-10-12 BIORoxx GmbH Verwendung von blutgerinnungshemmenden verbindungen als rodentizide

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL92011A0 (en) 1988-10-19 1990-07-12 Abbott Lab Heterocyclic peptide renin inhibitors
DE4035961A1 (de) * 1990-11-02 1992-05-07 Thomae Gmbh Dr K Cyclische iminoderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
DE4121947A1 (de) 1991-07-03 1993-01-07 Basf Ag 2-(3-(4-amidino-phenyl))-propionsaeurederivate, ihre herstellung und verwendung
US5703208A (en) 1994-06-17 1997-12-30 Corvas International, Inc. 3-amino-2-oxo-1-piperidineacetic derivatives as enzyme inhibitors
WO1998016523A2 (en) 1996-10-11 1998-04-23 Cor Therapeutics, Inc. Selective factor xa inhibitors
US6281227B1 (en) 1996-12-13 2001-08-28 Aventis Pharma Deutschland Gmbh Sulfonic acid sulfonylamino n-(heteroaralkyl)-azaheterocyclylamide compounds
US6602864B1 (en) 1996-12-13 2003-08-05 Aventis Pharma Deutschland Gmbh Sulfonic acid or sulfonylamino N-(heteroaralkyl)-azaheterocyclylamide compounds
PL333921A1 (en) 1996-12-13 2000-01-31 Rhone Poulenc Rorer Pharma N-(heteroalkyl)-azaheterocyclyamides of sulphonic acids or other n-(heteroalkyl)-azaheterocyclylamide compounds
US6187797B1 (en) 1996-12-23 2001-02-13 Dupont Pharmaceuticals Company Phenyl-isoxazoles as factor XA Inhibitors
IL123986A (en) 1997-04-24 2011-10-31 Organon Nv Medicinal compounds
US6525042B1 (en) * 1997-09-30 2003-02-25 Daiichi Pharmaceutical Co., Ltd. Sulfonyl derivatives
DE69934093T2 (de) 1998-01-27 2007-06-21 Aventis Pharmaceuticals Inc. SUBSTITUIERTE OXOAZAHETEROCYCLYL FAKTOR Xa HEMMER
WO1999054411A1 (en) 1998-04-22 1999-10-28 Showa Denko K.K. Particulate metal oxide with evenly fluorinated surface, process for producing the same, and use
DK1150976T3 (da) 1998-12-31 2003-06-02 Aventis Pharma Inc 3-(Thiosubstituerede amido)lactamer, der er nyttige som inhibitorer af matrixmetalloproteinase
JP2002536437A (ja) 1999-02-09 2002-10-29 ブリストル−マイヤーズ スクイブ カンパニー ＦＸａのラクタム抑制剤および方法
WO2000055188A1 (en) * 1999-03-16 2000-09-21 C & C Research Laboratories Substituted proline derivatives and medicinal compositions containing the same
WO2000069465A1 (en) 1999-05-12 2000-11-23 Ono Pharmaceutical Co., Ltd. Anticancer agents containing ep1 antagonists as the active ingredient
CA2382755A1 (en) 1999-07-28 2001-02-01 Aventis Pharmaceuticals Products Inc. Substituted oxoazaheterocyclyl compounds
HUP0304058A2 (hu) 2001-01-30 2004-04-28 Bristol-Myers Squibb Company Xa faktor szulfonamid-laktám inhibitorok és alkalmazásuk és ezeket tartalmazó gyógyszerkészítmények
GB0114005D0 (en) * 2001-06-08 2001-08-01 Glaxo Group Ltd Chemical compounds
GB0114004D0 (en) * 2001-06-08 2001-08-01 Glaxo Group Ltd Chemical compounds
GB0228552D0 (en) * 2002-12-06 2003-01-15 Glaxo Group Ltd Chemical compounds
GB0228533D0 (en) * 2002-12-06 2003-01-15 Glaxo Group Ltd Crystalline form

Also Published As

Publication number Publication date
ZA200309367B (en) 2004-08-02
CA2449629A1 (en) 2002-12-19
US7186717B2 (en) 2007-03-06
PL368082A1 (en) 2005-03-21
HUP0400156A2 (hu) 2004-07-28
KR20040004706A (ko) 2004-01-13
EP1395553A1 (en) 2004-03-10
ES2235050T3 (es) 2005-07-01
GB0114005D0 (en) 2001-08-01
AR036086A1 (es) 2004-08-11
WO2002100830A1 (en) 2002-12-19
HUP0400156A3 (en) 2008-10-28
EP1395553B1 (en) 2005-02-16
ATE289294T1 (de) 2005-03-15
CN1256324C (zh) 2006-05-17
US20070155745A1 (en) 2007-07-05
JP4242274B2 (ja) 2009-03-25
JP2004537530A (ja) 2004-12-16
NZ530004A (en) 2005-08-26
NO326689B1 (no) 2009-01-26
US20070142375A1 (en) 2007-06-21
AU2002311451B2 (en) 2006-03-02
US7517879B2 (en) 2009-04-14
PT1395553E (pt) 2005-06-30
CZ20033325A3 (cs) 2004-08-18
DK1395553T3 (da) 2005-06-06
IL159195A0 (en) 2004-06-01
NO20035440D0 (no) 2003-12-05
CO5540285A2 (es) 2005-07-29
SI1395553T1 (en) 2005-06-30
KR100877245B1 (ko) 2009-01-07
US7326785B2 (en) 2008-02-05
MXPA03011384A (es) 2004-04-05
MY136859A (en) 2008-11-28
US20070142374A1 (en) 2007-06-21
US20050107379A1 (en) 2005-05-19
TWI298719B (en) 2008-07-11
DE60203006D1 (de) 2005-03-24
CN1538955A (zh) 2004-10-20
HK1063471A1 (en) 2004-12-31
US7429587B2 (en) 2008-09-30
DE60203006T2 (de) 2006-03-30

Similar Documents

Publication Publication Date Title
BR9909565A (pt) Derivados bicìclicos do ácido hidroxâmico
BRPI0407734A (pt) derivados de adamantano, processo para sua preparação e composições farmacêuticas os contendo
BR0315720A (pt) Composto, método para a profilaxia ou tratamento de uma condição clìnica em um mamìmefero, formulação farmacêutica, combinação, uso de um composto, processo para a preparação de um composto, e, intermediário
BRPI0409498A (pt) uso de um composto, formulação farmacêutica, composto, composição farmacêutica, e, processo para preparação de um composto
YU56995A (sh) Soli derivata indola
BR9808953A (pt) Composto, processo para tratar um distúrbio mediado pela ciclooxigenase-2 em um paciente, e, composição farmacêutica
BRPI0316264B8 (pt) compostos, seu uso e formulação farmacêutica que os contém
BRPI0409109A (pt) novos compostos
BR9917155A (pt) Compostos triciclicos e o seu uso em medicina;processo para a sua preparação e composições farmacêuticas contendo os mesmos
BR0214142A (pt) Derivados e intermediários de n-adamantilmetila como composições farmacêuticas e processos para sua preparação
BRPI0317717B8 (pt) composto, composição farmacêutica, e uso de um composto
BRPI0212455B8 (pt) composto derivado de fenetanolamina para o tratamento de doenças respiratórias, formulação farmacêutica, combinação, e, uso do mesmo
BR0214469A (pt) 17alfa-alquil-17beta-óxi-estratrienos e produtos intermediários para sua preparação, aplicação dos 17alfa-alquil-17beta-óxi-estratrienos para a preparação de medicamentos bem como preparações farmacêuticas
EA200201271A1 (ru) Ингибиторы 11-бета-гидроксистероиддегидрогеназы типа 1
BR0214243A (pt) Derivado de sulfonamida processo para a preparação de um derivado de sulfonamida e seus sais fisiologicamente aceitáveis, composição farmacêutica e uso de um derivado de sulfonamida
BRPI0512974A (pt) novos derivados de hidantoìna para o tratamento de doenças obstrutivas das vias aéreas
SE0100569D0 (sv) New compounds
BRPI0108024B8 (pt) composto, processo para a preparação de um composto, composição farmacêutica, uso do composto, novo intermediário e processo para a preparação de um novo intermediário
MY136859A (en) Pyrrolidine derivatives as factor xa inhibitors
AR025103A1 (es) Quelantes quimicos para la reversion del bloqueo neuromuscular inducido por farmacos
BR9713921A (pt) Composto, composição farmacêutica, processo para tógico capaz de ser modulado através da inibição do fator xa
BR0012478A (pt) Derivados de aminotiazóis, sua preparação e composição farmacêuticas contendo os mesmos
BR9911274A (pt) Derivados da artemisinina, seus processos de preparação e as composições farmacêuticas que os contêm
BRPI0411729A (pt) dicetopiperazinas substituìdas e seu uso como antagonistas da oxitocina
BR0309896A (pt) Compostos, uso em um composto, composição farmacêutica, composição cosmética, uso cosmético de uma composição

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B11E Dismissal acc. art. 34 of ipl - requirements for examination incomplete
B11T Dismissal of application maintained [chapter 11.20 patent gazette]